Abstract:Rationale: Genome editing by CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 is evolving rapidly. Recently, second-generation CRISPR/Cas9 activation systems based on nuclease inactive dead (d)Cas9 fused to transcriptional transactivation domains were developed for directing specific guide (g)RNAs to regulatory regions of any gene of interest, to enhance transcription. The application of dCas9 to activate cardiomyocyte transcription in targeted genomic loci in vivo has not been demonstrated so far. Objective: We aimed to develop a mouse model for cardiomyocyte-specific, CRISPR-mediated transcriptional modulation, and to demonstrate its versatility by targeting Mef2d and Klf15 loci (2 well-characterized genes implicated in cardiac hypertrophy and homeostasis) for enhanced transcription. Methods and results: A mouse model expressing dCas9 with the VPR transcriptional transactivation domains under the control of the Myh (myosin heavy chain) 6 promoter was generated. These mice innocuously expressed dCas9 exclusively in cardiomyocytes. For initial proof-of-concept, we selected Mef2d, which when overexpressed, led to hypertrophy and heart failure, and Klf15, which is lowly expressed in the neonatal heart. The most effective gRNAs were first identified in fibroblast (C3H/10T1/2) and myoblast (C2C12) cell lines. Using an improved triple gRNA expression system (TRISPR [triple gRNA expression construct]), up to 3 different gRNAs were transduced simultaneously to identify optimal conditions for transcriptional activation. For in vivo delivery of the validated gRNA combinations, we employed systemic administration via adeno-associated virus serotype 9. On gRNA delivery targeting Mef2d expression, we recapitulated the anticipated cardiac hypertrophy phenotype. Using gRNA targeting Klf15, we could enhance its transcription significantly, although Klf15 is physiologically silenced at that time point. We further confirmed specific and robust dCas9VPR on-target effects. Conclusions: The developed mouse model permits enhancement of gene expression by using endogenous regulatory genomic elements. Proof-of-concept in 2 independent genomic loci suggests versatile applications in controlling transcription in cardiomyocytes of the postnatal heart.

The Function of the MEF2 Family of Transcription Factors in Cardiac Development, Cardiogenomics, and Direct Reprogramming

Role of MEF2 in Cardiac Development and Cardiovascular Diseases

Myocyte Enhancer Factor 2C and Its Directly-Interacting Proteins: A Review

The evolutionary ancient MEIS transcription factors actuate lineage-specific transcription to establish cardiac fate

Heart tube morphogenesis is regulated by segment-specific gene regulatory networks controlled by MEF2C

Myocardin-related transcription factors are required for cardiac development and function

The transcription factor EBF1 non-cell-autonomously regulates cardiac growth and differentiation

Translation of Myocyte Enhancer Factor-2 is Induced by Hypertrophic Stimuli in Cardiomyocytes Through a Calcineurin-dependent Pathway.

Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology.

P2570Synergistic Activation of the Cardiac Enhancer Landscape During Reprogramming

Requirements of Myocyte-Specific Enhancer Factor 2a in Zebrafish Cardiac Contractility

Cardiac Transcription Factors and Regulatory Networks

Mechanosensitive Gene Regulation by Myocardin-Related Transcription Factors is Required for Cardiomyocyte Integrity in Load-Induced Ventricular Hypertrophy.

Isoform Specific Effects of Mef2C During Direct Cardiac Reprogramming.

CHAMP, a Novel Cardiac-Specific Helicase Regulated by MEF2C.

MEF2 signaling and human diseases

Abstract We033: Heart-Specific Histone Methyltransferase SMYD1 Promotes Cardiac Maturation in the Direct Conversion of Human Fibroblasts into Cardiomyocytes.

The Research Progress of MEF2 Gene Family

Cooperative Interaction between the Basic Helix-loop-helix Transcription Factor dHAND and Myocyte Enhancer Factor 2C Regulates Myocardial Gene Expression

CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart

Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancer factor 2a to control embryonic cardiac contractility.